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Abstract
Purpose: The aim of this study was to assess the diagnostic performance of ECG-gated non-contrast-enhanced quiescent
interval single-shot (QISS) magnetic resonance angiography at a magnetic field strength of 3 Tesla in patients with
advanced peripheral arterial occlusive disease (PAOD).
Method and Materials: A total of 21 consecutive patients with advanced PAOD (Fontaine stage IIb and higher) referred for
peripheral magnetic resonance angiography (MRA) were included. Imaging was performed on a 3 T whole body MR. Image
quality and stenosis diameter were evaluated in comparison to contrast-enhanced continuous table and TWIST MRA (CE-
MRA) as standard of reference. QISS images were acquired with a thickness of 1.5 mm each (high-resolution QISS, HR-QISS).
Two blinded readers rated the image quality and the degree of stenosis for both HR-QISS and CE-MRA in 26 predefined
arterial vessel segments on 5-point Likert scales.
Results: With CE-MRA as the reference standard, HR-QISS showed high sensitivity (94.1%), specificity (97.8%), positive
(95.1%), and negative predictive value (97.2%) for the detection of significant ($50%) stenosis. Interreader agreement for
stenosis assessment of both HR-QISS and CE-MRA was excellent (k-values of 0.951 and 0.962, respectively). As compared to
CR-MRA, image quality of HR-QISS was significantly lower for the distal aorta, the femoral and iliac arteries (each with p,
0.01), while no significant difference was found in the popliteal (p = 0.09) and lower leg arteries (p = 0.78).
Conclusion: Non-enhanced ECG-gated HR-QISS performs very well in subjects with severe PAOD and is a good alternative
for patients with a high risk of nephrogenic systemic fibrosis.
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Introduction
Peripheral arterial occlusive disease (PAOD) has a prevalence of
12 to 20% in individuals of over 65 years and is one of the most
important and cost-intensive vascular diseases [1]. Cross-sectional
diagnostic imaging can determine severity and localization of
stenosis and is therefore indispensable for planning of surgical and
interventional procedures.
CT angiography (CTA) offers a high spatial resolution without
the risks of an invasive procedure [2]. However, well known
drawbacks of contrast-enhanced CT are the risk of iodinated
contrast nephropathy and the ionizing radiation. As an alternative,
contrast-enhanced MR angiography (CE-MRA) employing gad-
olinium-based contrast agents has shown to be equally accurate for
the detection of vascular stenosis within the entire lower limb
without a disturbing overlay from bone or calcified plaques [3].
Thus, CE-MRA is used as the primary imaging modality for
PAOD patients in many centers [4].
However, since the risk of nephrogenic systemic fibrosis (NSF)
in patients with chronic renal failure was reported [5,6], interest in
non-enhanced MR angiography techniques has markedly in-
creased [7–9]. This applies in particular to the diagnostic
investigation of patients suffering from PAOD as this population
has a high prevalence of chronic renal failure [10]. To compound
this problem, a complete CE-MRA investigation from the distal
aorta to the pedal arteries typically requires a relatively large
amount of contrast agent.
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In recent studies, the non-enhanced electrocardiogram (ECG)-
triggered quiescent interval single shot (QISS)-MR angiography
has shown promising results [11–16]. On 1.5 Tesla MRI systems,
this two-dimensional sequence proved to be resistant against
changes in heart beat and showed good accuracy in vessels with
high grade stenosis. At a slice thickness of 3 mm, sensitivity ranged
from 84.9% to 98.6% and specificity from 94.6% to 96.8% [11–
13,16].
Despite of the positive results, further research is needed before
QISS-MRA can be employed for general clinical use in PAOD
patients. Reported drawbacks include poor image quality in the
distal aorta and iliac arteries as well as the tendency to
overestimate stenosis [13]. In previous studies, subjects with
suspected PAOD but no significant stenosis were part of the
patient collective. The inclusion of patients with a good vascular
status, however, can lead to an overestimation of the diagnostic
accuracy of QISS as MR imaging in PAOD patients has shown to
be more challenging. With respect to these points, a systematic
evaluation of the QISS-MRA on state-of-the-art high field MR
systems in patients with advanced PAOD seems worthwhile.
The aim of this study was to assess the diagnostic performance
of a high-resolution prototype of QISS-MRA (HR-QISS) in
comparison to the reference standard of CE-MRA in patients with
known PAOD. In contrast to previous studies, HR-QISS was
performed on a 3 Tesla system, allowing for a slice thickness of
1.5 mm for the whole scan volume at a reasonable imaging time.
Materials and Methods
This prospective study was approved by the local ethics
committee of the Medical Faculty of the Ludwig-Maximilians-
Universtity Munich, Germany. Between April 2012 and March
2013, 21 consecutive patients with advanced peripheral arterial
occlusive disease (PAOD) were included. All patients had been
referred for MRA of the lower extremities. Written informed
consent was obtained from all patients. We evaluated the
diagnostic performance and image quality of the non-enhanced
HR-QISS MRA in comparison to contrast-enhanced MRA as
standard of reference.
Inclusion criteria were (1) known advanced PAOD (Fontaine
Stage IIb to IV [17]), and (2) the clinical indication for peripheral
cross-sectional angiography of the lower extremities. Exclusion
criteria were (1) contraindications to MRI (cardiac pacemaker,
cochlea implants etc.), (2) renal impairment as indicated by point-
of-care testing of an estimated glomerular filtration rate of less
than 30 ml/min/1.73 m2, (3) known adverse reactions to gado-
linium chelates, and (4) the inability to complete non-enhanced
HR-QISS and/or CE-MRA.
Imaging was performed on a 3 Tesla whole body MR scanner
(MAGNETOM Verio, Siemens Healthcare, Erlangen, Germany),
with the patients in supine position and with feet first. In order to
cover all arteries from the distal aorta to the pedal vessels, we used
a dedicated peripheral angiography array coil with a 36-element
coil design, supplemented by one or two 6-element body matrix
coils to cover pelvis and lower abdomen and 12 to 16 elements of
the spine matrix coil depending on the patient’s size.
Non-enhanced HR-QISS
QISS is an ECG-triggered single-shot two-dimensional bal-
anced steady-state free precession (bSSFP) pulse sequence that was
introduced in 2010 [14]. The quiescent interval as the key feature
of the sequence is a waiting period after the R-spike without any
radiofrequency excitation (Figure 1). The idea of the quiescent
interval is that it coincides with the period of fast systolic arterial
flow. By insuring maximum inflow of unsaturated spins into the
investigated slice, a better contrast between the vessel and the
surrounding soft-tissues is expected. Presaturation is used to
suppress background tissue and venous signal while arterial signal
is enhanced due to inflow into the investigated slice from proximal
to distal during the quiescent interval. The signal acquisition is
prepared by an alpha/2 preparation pulse, which is played out
before the first excitation.
We used a non-commercial version of the QISS sequence that
was modified for use in this research study. In contrast to previous
studies, a slice thickness of only 1.5 mm and no overlap between
adjacent slices was used for all regions from the distal aorta to the
pedal arteries. In order to cover all vessels from the level of the
infrarenal aorta to the pedal arteries, seven contiguous groups of
128 slices were acquired, covering 192 mm each. No breath
holding maneuvers were used for any of the seven groups. Detailed
information of the imaging parameters of HR-QISS and CE-
MRA are presented in Table 1.
Contrast-enhanced MRA (CE-MRA)
CE-MRA was performed with gadobutrol (Gadovist, Bayer
Schering Pharma, Berlin, Germany) using a dual-injection
technique consisting of a continuously moving table (CMT)
MRA [18], followed by a time-resolved MRA for dedicated
dynamic imaging of the calves [19].
First, a test bolus of 2 ml diluted gadobutrol (1 ml gadobutrol,
1 ml 0.9% NaCl) was administered at a flow rate of 1 ml/sec, its
arrival was monitored using a dynamic 2D FLASH protocol in the
abdomen. The signal in the abdominal aorta was used to
determine the bolus arrival time. The subsequent CMT acquisi-
tion covered the whole arterial tree from the infrarenal aorta to the
pedal arteries. It was obtained with an injection of 20 ml diluted
gadobutrol (10 ml gadobutrol, 10 ml 0.9% NaCl) at a flow rate of
1 ml/sec, immediately followed by two 25 ml saline chasers at
flow rates of 1 ml/sec and 0.5 ml/sec, respectively.
For the dynamic imaging of the arteries of the calves, a coronal
time-resolved imaging sequence with stochastic trajectories
(TWIST) [19] utilizing 10 ml diluted gadobutrol (5 ml gadobutrol,
5 ml 0.9% NaCl) at a flow rate of 1 ml/sec followed by a 25 ml
saline chaser was employed.
Image Analysis
All images were viewed on a 3D workstation using standard
three-dimensional reconstruction software (syngoMMWP VE26A,
Siemens Healthcare, Erlangen, Germany). Readings of HR-QISS
and CE-MRA were performed separately by two blinded and
Figure 1. Pulse sequence diagram of the QISS sequence
(modified after: Edelman RR et al., MRM 2009) [14]. Saturation
of imaging slice and tracking saturation of venous signal are applied
100 ms after the R-spike. The subsequent quiescent interval allows for
inflow of non-saturated blood spins before a single-shot 2D image is
acquired.
doi:10.1371/journal.pone.0091078.g001
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board-certified radiologists with 12 (K.N.) and 10 years (D.T.) of
experience in MRA, respectively. In case of disagreement between
the readers, a consensus was reached in a separate session. Source
images, multiplanar reformatted reconstructions (MPRs), and
maximum intensity projections (MIPs) were allowed to be used for
all datasets. Readers were blinded to the patients’ medical
histories, clinical findings, and previous examinations.
The degree of stenosis and image quality were graded for 27
anatomic segments in each patient: for the infrarenal aorta and for
13 further segments in each lower extremity: common iliac artery,
external iliac artery, common femoral artery, proximal half of
superficial femoral artery, distal half of superficial femoral artery,
popliteal artery, proximal half of anterior tibial artery, distal half of
anterior tibial artery, tibioperoneal trunk, proximal half of
peroneal artery, distal half of peroneal artery, proximal half of
posterior tibial artery, and distal half of posterior tibial artery [13].
The degree of vessel stenosis was graded visually and in
accordance with previous studies on non-enhanced QISS-MRA
[12–14]. The degree of stenosis was defined in each vascular
segment using a 5-point Likert scale: 0, normal; 1, luminal
narrowing of ,50%; 2, one lesion with luminal narrowing of $
50%; 3, two or more lesions with luminal narrowing of $50%; 4,
occlusion. Segments with grades from 2 to 4 were considered as
significantly stenosed.
CE-MRA was represented by both CMT- and dynamic
TWIST-MRA. In accordance to previous major trials, CMT-
MRA was used for the arterial tree from the distal aorta to the
popliteal arteries, while TWIST-MRA served as the reference
standard for the calves [13,20]. We did not include the TWIST-
MRA as a third technique in our statistical analysis as it covered
only the calves.
Image quality was rated for both CE-MRA and HR-QISS using
a 5-point Likert scale: (0) non-diagnostic; (1) poor; (2) fair; (3) good;
(4) excellent. This rating included the issue of venous contamina-
tion which is a common problem in MRA of the peripheral
arteries. Segments with stents or arterial prosthesis were excluded
from analysis due to artifacts in both techniques. Any other failure
to visualize a segment using one of the techniques was considered
an incorrect assessment by the respective sequence. For the
evaluation of image quality, segments with no visible artery due to
total occlusion in the whole segment of the evaluated artery were
excluded.
Statistical Analysis
We performed all statistical analyses using SPSS Statistics 20
(IBM, Armonk/NY, USA). Normal distribution was assessed using
the Kolmogorov-Smirnov test. P-values below 0.05 were assumed
to indicate statistical significance.
The average stenosis scores of HR-QISS and CE-MRA were
compared using a nonparametric Wilcoxon signed-rank test. In
addition to the segment-based analysis, per-region and per-limb
analyses were performed. For these analyses, the segment grades
were averaged for each of the three regions (distal aorta and pelvis,
thigh, and calf) and each limb. A subgroup analysis was performed
to assess the performance of HR-QISS in distinguishing between
high-grade stenosis (grades 2 and 3) and occlusion (grade 4).
Sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) of the non-enhanced HR-QISS
for the detection of significant ($50%, grades 2–4) stenoses were
assessed relative to the CE-MRA as the reference standard. For
the purpose of per-region and per-limb calculations, the highest
grade – indicating the most severe stenosis – was identified for the
region and limb, respectively.
Diagnostic image quality values of HR-QISS and CE-MRA
were compared by using the paired t-test and were reported as
means 6 standard deviation. The level of interreader agreement
of stenosis severity assessment for both MRA techniques was
assessed by Cohen’s Kappa (k) [21].
Results
Evaluation of QISS-MRA and CE-MRA was possible in all
included patients (N= 21). 13 patients were male, 8 were female.
Mean age was 72.967.8 years. The clinical manifestation of
PAOD reached from Fontaine stage IIb to stage IV. In particular,
it was stage IIb in 11 patients, stage III in 4 patients, and stage IV
in 6 patients. Assuming a typical heart rate of 72 BPM (RR-
interval 0.833 sec), the net imaging time for HR-QISS was 12.4
minutes. Including table movement and shimming times, the
actual mean total time of HR-QISS examination was 21 minutes.
Table 1. Imaging parameters of HR-QISS and contrast enhanced MRA sequences.
Imaging Parameter Non-enhanced HR-QISS Contrast enhanced MRA Contrast enhanced dynamic (TWIST)
Acquisition mode 2D 3D 3D
Acquisition time 896 cardiac cycles1 2:24 min 1:44 min
TR (msec) 3.35 2.81 3.03
TE (msec) 1.36 1.09 1.11
Flip angle (degrees) 50–60 24 24
Field of View (mm) 40062606192 35062636350 35062636350
Voxel size (mm) 1.061.061.5 1.061.061.3 1.261.262.5
Phase partial Fourier factor 5/8 6/8 6/8
Slice partial Fourier factor – 6/8 6/8
GRAPPA acceleration factor Two Three Three
Bandwidth (Hz/px) 833 1000 650
Fat suppression Yes No No
1HR-QISS acquisition time depends on the subjects’ heart rate; GRAPPA: Generalized autocalibrating partially parallel acquisition; HR-QISS: High-resolution quiescent
interval single shot sequence; MRA: Magnetic resonance angiography; TE: Echo time; TR: Repetition Time; TWIST: Time-resolved imaging with stochastic trajectories.
doi:10.1371/journal.pone.0091078.t001
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Overall, 551 of the 567 arterial segments were assessable by
HR-QISS, while 555 out of 567 arterial segments were assessable
by CE-MRA. Segments with a stent (8) or a vascular prosthesis (4)
were non-assessable and had to be excluded in both MRA
techniques. Four segments were non-assessable in HR-QISS due
to signal dropout caused by endoprosthesis. For the evaluation of
image quality, 42 segments with no visible artery due to total
occlusion in the whole segment of the respective artery were
excluded.
In total, 42 limbs, 63 regions, and 551 anatomic segments were
assessed with respect to the degree of stenosis and 42 limbs, 58
regions and 513 segments with regard to image quality.
Overall Diagnostic Performance of Non-enhanced MRA
For HR-QISS, 174 of 551 segments (31.6%) were rated as
significantly stenosed ($50%) and 377 segments (68.4%) as not
significantly stenosed (,50%). A significant stenosis was diagnosed
in 176 of 551 segments (31.9%) according to the rating of the CE-
MRA. There was no systematic over- or underestimation of the
presence of significant stenosis using non-enhanced MRA (p.
0.05).
In the segment-based pairwise comparison, non-enhanced
MRA showed no significant difference in the stenosis grades in
any of the 14 anatomical segments (each with p.0.05). Overall,
for HR-QISS, a sensitivity of 94.1%, a specificity of 97.8%, a
positive predictive value (PPV) of 95.1%, and a negative predictive
value (NPV) of 97.2% were obtained.
In the region-based analysis, non-enhanced and contrast-
enhanced MRA techniques showed similar maximum stenosis
grades in all three regions (distal aorta and pelvis, thigh, and calf;
each with p.0.05). HR-QISS showed a sensitivity of 97.0%, a
specificity of 96.7%, a PPV of 97.0%, and a NPV of 96.7%.
In the limb-based analysis, no difference was found in the
pairwise comparison. All limbs were assigned the same maximum
stenosis grade in the HR-QISS as compared to CE-MRA,
resulting in limb-based sensitivity, specificity, PPV and NPV of
each 100%.
The results of the diagnostic performance of HR-QISS for the
detection of stenosis in the lower extremities are summarized in
Table 2. Clinical examples are shown in Figures 2, 3.
Distinguishing between High-grade Stenosis and
Occlusion
In summary, 176 segments were rated as significantly stenosed
or occluded (grade 2 or higher) in the CE-MRA reading. Within
this subgroup, using HR-QISS, 62 segments (35.2%) were rated as
highly stenosed (grades 2 and 3) and 114 segments (64.8%) were
rated as occluded (grade 4). For CE-MRA, 58 segments (33.0%)
were classified to have a high-grade stenosis and 118 segments
(77.0%) to have an occlusion.
For the detection of an occlusion in all segments with a stenosis
grade of 2 and higher in the CE-MRA reference standard, HR-
QISS showed a sensitivity of 93.1%, a specificity of 93.2%, a PPV
of 96.5%, and a NPV of 87.1%.
Table 2. Diagnostic performance of non-enhanced high-resolution QISS-MRA vs. contrast enhanced MRA, N= 21.
Per segment Per region Per limb
Sensitivity (%) 94.1 (89.8–96.7) 97.0 (83.3–99.4) 100.0 (91.6–100.0)
Specificity (%) 97.8 (95.8–98.8) 96.7 (84.7–99.5) 100.0 (91.6–100.0)
PPV (%) 95.1 (91.2–98.3) 97.0 100.0
NPV (%) 97.2 (95.1–98.6) 96.7 100.0
Numbers in brackets are 95% confidence intervals. NPV: negative predictive value; PPV: positive predictive value.
doi:10.1371/journal.pone.0091078.t002
Figure 2. Contrast-enhanced continuous table movement (left)
and non-enhanced HR-QISS (right) MRA in a 68 y/o male
patient suffering from PAOD stage IV. The examination was
performed after percutaneous transluminal angioplasty (PTA) of the
right superficial femoral artery. Both CE-MRA and HR-QISS depict
multiple significant (.50%) stenoses in the right superficial femoral
artery, an occlusion of the right anterior tibial artery and a single
significant short-distance stenosis in the proximal left anterior tibial
artery. Note the slightly better image quality of CE-MRA in the distal
aorta due to motion artifacts in the HR-QISS sequence. On the other
hand, non-enhanced HR-QISS shows less venous overlay.
doi:10.1371/journal.pone.0091078.g002
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Comparison of Diagnostic Image Quality
Subjective diagnostic image quality of the anatomical segments
was rated as excellent or good in 333/513 (64.9%) segments using
HR-QISS and in 393/513 (76.6%) segments using CE-MRA,
respectively.
Overall, mean image quality of QISS-MRA was 2.5860.91,
while it was significantly higher in CE-MRA (2.8461.06, p,0.01,
paired t-test). Image quality of QISS-MRA was significantly lower
for the regions of the distal aorta and the pelvis (p,0.01), and for
the region of thigh (p,0.01). No significant difference was found
in the region of the calf (p = 0.78). Table 3 shows detailed
information on diagnostic image quality comparison.
Interreader Agreement
There was excellent interreader agreement between stenosis
scores (significant vs. non-significant stenosis) for both QISS-MRA
(k=0.951) and CE-MRA (k=0.962).
Discussion
In this prospective MRA study, non-enhanced ECG-gated high-
resolution QISS-MRA was successfully applied for the visualiza-
tion of the peripheral arteries on a 3 Tesla MR system in patients
with advanced PAOD. As compared to contrast-enhanced MRA
as standard of reference, sensitivity, specificity, PPV and NPV
were high. The overall image quality of HR-QISS was fair, but
significantly lower in the distal aorta, the iliac and the femoral
arteries when compared to CE-MRA. No significant difference
was found in the more distal anatomical segments.
Our findings are consistent with and extend those of previous
studies on non-enhanced MRA of the lower extremities. While
several well-known non-enhanced MRA techniques such as Time-
of-Flight (TOF)-MRA [22], phase contrast MRA [23], and Turbo-
Spin-Echo (TSE) [18,24,25], have shown to be more or less
inadequate for the investigation of PAOD, QISS-MRA has
already shown satisfactory results in the assessment of the
peripheral arteries. In comparison to CE-MRA, sensitivities
ranged from 84.9% to 98.6% and specificities from 94.6% to
96.8% [11–13,16].
We could show that HR-QISS with a slice thickness of 1.5 mm
at 3 Tesla performs very well in the presence of advanced disease.
HR-QISS apparently profits from an improved contrast between
arteries and surrounding soft tissue due to a higher field strength.
In our patient collective, less than 1% of segments were not
assessable in HR-QISS but only in CE-MRA. Sensitivity and
specificity of HR-QISS were 94.1% and 97.8%, respectively.
Remarkably, in contrast to previous studies, no significant
difference between HR-QISS and CE-MRA was found with
regard to stenosis grade in any of the anatomical segments.
Furthermore, the ability of HR-QISS to distinguish between high-
grade stenosis and occlusion was very good. An overestimation of
severe stenosis as it has been reported for QISS-MRA techniques
at 1.5 Tesla could not be observed in our study.
In our study, we included only patients with a confirmed PAOD
of Fontaine stage IIb and higher. It is important to note that
previous studies had included subjects in which PAOD is
suspected but not necessarily confirmed. Advanced PAOD,
however, can cause major variations in blood flow velocity among
different segments, making MR imaging considerably more
difficult. PAOD patients also often suffer from cardiac arrhythmia
and they tend to be elderly and may suffer from back pain or
restless legs which can cause motion artifacts. Therefore, we
excluded patients with absent or only mild symptoms of PAOD in
order not to overestimate the diagnostic performance of QISS in
its target patient group.
Although image quality is less crucial than diagnostic accuracy,
it remains a drawback in QISS-MRA. Similarly to previous
reports, image quality in the distal aorta, pelvis and thigh was
significantly lower in HR-QISS. This is probably also due to the
fact that we completely avoided breath holding in order to increase
patient comfort.
The main advantage of HR-QISS is that no gadolinium-based
contrast agent is needed, which can potentially cause nephrogenic
systemic fibrosis [5,6]. As patients suffering from PAOD have a
high prevalence of chronic renal failure, HR-QISS is particularly
well-suited for this patient population [10]. Moreover, non-
enhanced techniques increases patient comfort, and cost for
contrast agent can be avoided. Another benefit of QISS as
compared to other non-enhanced techniques is that imaging
parameters typically do not have to be tailored to the patient’s
heart rate or other factors. In case of bulk motion, the slice group
containing the region of concern can be repeated.
Figure 3. Contrast-enhanced (left) and non-enhanced HR-QISS
(right) MRA in a 72 y/o male with PAOD stage IIb. CE-MRA and
HR-QISS findings show excellent correlation. Both techniques reveal a
long-distance occlusion of the right superficial femoral artery. The right
superficial femoral artery is reconstituted via collaterals from the deep
femoral artery. Further occlusions are found in both fibular arteries and
the proximal left anterior tibial artery. High-grade stenoses are located
in the right anterior tibial artery and in the left superficial femoral artery.
doi:10.1371/journal.pone.0091078.g003
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While HR-QISS offers many advantages, it is also important to
bear in mind that total examination times of over twenty minutes
can cause problems especially in elder and severely ill patients.
Recent technical developments, namely a QISS technique that
uses a highly undersampled radial k-space trajectory, has proven
to enable the acquisition of two to three slices per cardiac cycle
[26]. Thereby, it was possible to shorten the scan time for a
complete peripheral MRA to 2 minutes or less.
The presence of signal dropouts due to stents and metal clips is
another reason to prefer CE-MRA in certain patients. Also, even if
we did not encounter any problems with ECG gating, it has been
reported that low QRS voltage or poor lead contact can result in
artifacts [12,27]. ECG gating is the most popular method for
cardiac synchronization; however, it is subject to interference from
switching magnetic field gradients and radiofrequency pulses. In
this context, a recently presented approach of a self-navigated non-
enhanced QISS-MRA that does not require the use of ECG gating
appears promising [28].
We acknowledge a few limitations of our study. First,
correlations of MRA findings to the gold standard, invasive
DSA, were not performed. This reflects the fact that DSA is
mainly reserved for candidates for revascularization therapy at our
institution. We therefore used CE-MRA, which is generally
considered as the non-invasive gold standard [3,4]. Second, it was
not possible to completely blind the readers as to whether the
MRA examination was contrast-enhanced or not because of
distinguishing features such as contrast agent in the bladder cannot
be hidden. Third, the data analysis was performed on 5-point
Likert scales and we did not quantify artery diameters and stenosis
length. However, we think that this approach reflects the reading
of an MRA study as it is performed in clinical practice rather than
the evaluation by using additional quantitative tools.
Finally, we included a relatively small number of patients in this
study. We are convinced, however that it is sufficient to
demonstrate the eligibility of HR-QISS as we obtained excellent
results, although the study exclusively focused on critical patients
with a poor vascular status.
In conclusion, non-enhanced HR-QISS MRA at 3 Tesla shows
a high sensitivity and specificity in the evaluation of the peripheral
arteries at a reasonable imaging time. HR-QISS performs very
well even in patients even with advanced PAOD and is
particularly well suited for patients for which the administration
of contrast agent is associated with a high risk of NSF. It seems to
become apparent that QISS is the most suitable technique for
non-contrast-enhanced MR angiography of the lower extremities.
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